FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943893614> ?p ?o ?g. }

• W2943893614 abstract "There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with eculizumab.Patients with aHUS who participated in any of five parent eculizumab trials and received at least one eculizumab infusion were eligible for enrollment in a long-term follow-up study. Rates of thrombotic microangiopathy (TMA) manifestations off versus on eculizumab were evaluated. Additional endpoints included change from baseline estimated glomerular filtration rate (eGFR), long-term renal outcomes, and serious targeted treatment-emergent adverse events.Among 93 patients (0-80 years of age), 51 (55%) remained on eculizumab and 42 (45%) discontinued; for those who discontinued, 21 (50%) reinitiated therapy. Patients who reinitiated eculizumab had similar baseline clinical characteristics to patients who remained on eculizumab, with higher likelihood of genetic/autoimmune complement abnormalities, more prior TMAs, and longer disease course versus those who did not reinitiate. Mean eGFR improved rapidly and remained stable for up to 6 years on eculizumab. In patients who discontinued, there was a trend toward decreasing renal function over time from discontinuation. Additionally, off-treatment TMA manifestation rates were higher in those aged < 18 years at diagnosis, with identified genetic/autoimmune complement abnormalities, or history of multiple TMAs prior to eculizumab initiation. The safety profile was consistent with previous studies. Three definite and one possible meningococcal infections related to eculizumab were reported and resolved with treatment. Three deaths unrelated to eculizumab were reported.The current study confirms the efficacy and safety of eculizumab in aHUS, particularly with regard to long-term renal function and TMA events. Pediatric age at disease onset and presence of genetic or autoimmune complement abnormalities are risk factors for TMA events off treatment. Overall, patients who discontinue eculizumab may be at risk for additional TMA manifestations and renal function decreases. Discontinuation of eculizumab, with careful monitoring, is an option in select patients with consideration of patient preference, organ function normalization, and risk factors for relapse, including mutational analysis, age of onset, and history of multiple TMA episodes.ClinicalTrials.gov NCT01522170 , January 31, 2012." @default.
• W2943893614 created "2019-05-16" @default.
• W2943893614 creator A5008099099 @default.
• W2943893614 creator A5010002554 @default.
• W2943893614 creator A5017767151 @default.
• W2943893614 creator A5020275216 @default.
• W2943893614 creator A5037368498 @default.
• W2943893614 creator A5038495729 @default.
• W2943893614 creator A5061357967 @default.
• W2943893614 creator A5061747630 @default.
• W2943893614 creator A5082634620 @default.
• W2943893614 creator A5083723682 @default.
• W2943893614 creator A5091345735 @default.
• W2943893614 creator A5091587971 @default.
• W2943893614 date "2019-04-10" @default.
• W2943893614 modified "2023-10-16" @default.
• W2943893614 title "Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study" @default.
• W2943893614 cites W1917443989 @default.
• W2943893614 cites W2017235356 @default.
• W2943893614 cites W2052693906 @default.
• W2943893614 cites W2106675927 @default.
• W2943893614 cites W2118510193 @default.
• W2943893614 cites W2123753762 @default.
• W2943893614 cites W2159884188 @default.
• W2943893614 cites W2166637331 @default.
• W2943893614 cites W2264090971 @default.
• W2943893614 cites W2305176160 @default.
• W2943893614 cites W2311077515 @default.
• W2943893614 cites W2540481111 @default.
• W2943893614 cites W2565152113 @default.
• W2943893614 cites W2590258299 @default.
• W2943893614 cites W2727335336 @default.
• W2943893614 cites W2730107276 @default.
• W2943893614 cites W2746096526 @default.
• W2943893614 cites W2751882444 @default.
• W2943893614 cites W2804956348 @default.
• W2943893614 cites W2902241490 @default.
• W2943893614 cites W2914587352 @default.
• W2943893614 doi "https://doi.org/10.1186/s12882-019-1314-1" @default.
• W2943893614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6456946" @default.
• W2943893614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30971227" @default.
• W2943893614 hasPublicationYear "2019" @default.
• W2943893614 type Work @default.
• W2943893614 sameAs 2943893614 @default.
• W2943893614 citedByCount "68" @default.
• W2943893614 countsByYear W29438936142019 @default.
• W2943893614 countsByYear W29438936142020 @default.
• W2943893614 countsByYear W29438936142021 @default.
• W2943893614 countsByYear W29438936142022 @default.
• W2943893614 countsByYear W29438936142023 @default.
• W2943893614 crossrefType "journal-article" @default.
• W2943893614 hasAuthorship W2943893614A5008099099 @default.
• W2943893614 hasAuthorship W2943893614A5010002554 @default.
• W2943893614 hasAuthorship W2943893614A5017767151 @default.
• W2943893614 hasAuthorship W2943893614A5020275216 @default.
• W2943893614 hasAuthorship W2943893614A5037368498 @default.
• W2943893614 hasAuthorship W2943893614A5038495729 @default.
• W2943893614 hasAuthorship W2943893614A5061357967 @default.
• W2943893614 hasAuthorship W2943893614A5061747630 @default.
• W2943893614 hasAuthorship W2943893614A5082634620 @default.
• W2943893614 hasAuthorship W2943893614A5083723682 @default.
• W2943893614 hasAuthorship W2943893614A5091345735 @default.
• W2943893614 hasAuthorship W2943893614A5091587971 @default.
• W2943893614 hasBestOaLocation W29438936141 @default.
• W2943893614 hasConcept C111684460 @default.
• W2943893614 hasConcept C126322002 @default.
• W2943893614 hasConcept C159641895 @default.
• W2943893614 hasConcept C159654299 @default.
• W2943893614 hasConcept C203014093 @default.
• W2943893614 hasConcept C2777637130 @default.
• W2943893614 hasConcept C2777878052 @default.
• W2943893614 hasConcept C2777991916 @default.
• W2943893614 hasConcept C2778715236 @default.
• W2943893614 hasConcept C2779134260 @default.
• W2943893614 hasConcept C54847362 @default.
• W2943893614 hasConcept C71924100 @default.
• W2943893614 hasConcept C90924648 @default.
• W2943893614 hasConceptScore W2943893614C111684460 @default.
• W2943893614 hasConceptScore W2943893614C126322002 @default.
• W2943893614 hasConceptScore W2943893614C159641895 @default.
• W2943893614 hasConceptScore W2943893614C159654299 @default.
• W2943893614 hasConceptScore W2943893614C203014093 @default.
• W2943893614 hasConceptScore W2943893614C2777637130 @default.
• W2943893614 hasConceptScore W2943893614C2777878052 @default.
• W2943893614 hasConceptScore W2943893614C2777991916 @default.
• W2943893614 hasConceptScore W2943893614C2778715236 @default.
• W2943893614 hasConceptScore W2943893614C2779134260 @default.
• W2943893614 hasConceptScore W2943893614C54847362 @default.
• W2943893614 hasConceptScore W2943893614C71924100 @default.
• W2943893614 hasConceptScore W2943893614C90924648 @default.
• W2943893614 hasIssue "1" @default.
• W2943893614 hasLocation W29438936141 @default.
• W2943893614 hasLocation W29438936142 @default.
• W2943893614 hasLocation W29438936143 @default.
• W2943893614 hasLocation W29438936144 @default.
• W2943893614 hasLocation W29438936145 @default.
• W2943893614 hasLocation W29438936146 @default.
• W2943893614 hasLocation W29438936147 @default.
• W2943893614 hasOpenAccess W2943893614 @default.
• W2943893614 hasPrimaryLocation W29438936141 @default.

• next